BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911 AND Diagnosis
23 results:

  • 1. Explainable artificial intelligence to predict and identify prostate cancer tissue by gene expression.
    Ramírez-Mena A; Andrés-León E; Alvarez-Cubero MJ; Anguita-Ruiz A; Martinez-Gonzalez LJ; Alcala-Fdez J
    Comput Methods Programs Biomed; 2023 Oct; 240():107719. PubMed ID: 37453366
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
    Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
    Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Robotic-assisted Simple prostatectomy: An Intrafascial Approach for a prostate of 470 g.
    Poncel J; Celis V; Sayegh AS; Eppler M; Medina LG; Sotelo R
    Urology; 2023 Jun; 176():246-247. PubMed ID: 36965818
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer.
    Liu LL; Zhu LL; Lu ZG; Sun JD; Zhao J; Wang HF; Xiang ZL
    Cancer Imaging; 2023 Jan; 23(1):1. PubMed ID: 36600283
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study.
    Lozano-Lorca M; Barrios-Rodríguez R; Redondo-Sánchez D; Cózar JM; Arrabal-Martín M; García-Caballos M; Salcedo-Bellido I; Sánchez MJ; Jiménez-Moleón JJ; Olmedo-Requena R
    Qual Life Res; 2023 Apr; 32(4):977-988. PubMed ID: 36409391
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
    Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
    Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Artificial intelligence system shows performance at the level of uropathologists for the detection and grading of prostate cancer in core needle biopsy: an independent external validation study.
    Jung M; Jin MS; Kim C; Lee C; Nikas IP; Park JH; Ryu HS
    Mod Pathol; 2022 Oct; 35(10):1449-1457. PubMed ID: 35487950
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Differences in prostate cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable cancer Risk Factors, and Clinical Factors.
    Stopsack KH; Nandakumar S; Arora K; Nguyen B; Vasselman SE; Nweji B; McBride SM; Morris MJ; Rathkopf DE; Slovin SF; Danila DC; Autio KA; Scher HI; Mucci LA; Solit DB; Gönen M; Chen Y; Berger MF; Schultz N; Abida W; Kantoff PW
    Clin Cancer Res; 2022 Jan; 28(2):318-326. PubMed ID: 34667026
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Real world treatment utilization patterns in patients with castration-resistant prostate cancer.
    Vigneswaran HT; Warnqvist A; Andersson TML; Leval A; Eklund M; Nordström T; Eloranta S; Schain F; Dearden L; Liwing J; Mehra M; Nair S; Pettersson A; Akre O; Aly M
    Scand J Urol; 2021 Aug; 55(4):299-306. PubMed ID: 34096469
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Understanding the Relationship between Environmental Arsenic and prostate cancer Aggressiveness among African-American and European-American Men in North Carolina.
    Parada H; Wu T; Fry RC; Farnan L; Smith GJ; Mohler JL; Bensen JT
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33198142
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Diagnostic Performance of Monoexponential DWI Versus Diffusion Kurtosis Imaging in prostate cancer: A Systematic Review and Meta-Analysis.
    Si Y; Liu RB
    AJR Am J Roentgenol; 2018 Aug; 211(2):358-368. PubMed ID: 29812977
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Automated diagnosis of prostate cancer in multi-parametric MRI based on multimodal convolutional neural networks.
    Le MH; Chen J; Wang L; Wang Z; Liu W; Cheng KT; Yang X
    Phys Med Biol; 2017 Jul; 62(16):6497-6514. PubMed ID: 28582269
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Patterns of changing cancer risks with time since diagnosis of a sibling.
    Lee M; Czene K; Rebora P; Reilly M
    Int J Cancer; 2015 Apr; 136(8):1948-56. PubMed ID: 25267314
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The validity of the distress thermometer in prostate cancer populations.
    Chambers SK; Zajdlewicz L; Youlden DR; Holland JC; Dunn J
    Psychooncology; 2014 Feb; 23(2):195-203. PubMed ID: 24027194
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Using age-referenced prostate-specific antigen percentile to predict survival outcomes in screened Taiwanese men.
    Chen CH; Yao HH; Huang SW; Chuang CK; Hsu HS; Wang CJ; Pu YS
    Int J Cancer; 2013 Apr; 132(8):1927-32. PubMed ID: 22987331
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men.
    Tang P; Du W; Xie K; Deng X; Fu J; Chen H; Yang W
    Urol Oncol; 2013 Aug; 31(6):744-8. PubMed ID: 21868261
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Association of a positive family history with histopathology and clinical course in early-onset prostate cancer].
    Herkommer K; Paiss T; Merz M; Gschwend JE; Kron M
    Urologe A; 2006 Dec; 45(12):1532-9. PubMed ID: 17004091
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy.
    Paiss T; Herkommer K; Bock B; Heinz H; Vogel W; Kron M; Kuefer R; Hautmann RE; Gschwend JE
    Eur Urol; 2003 Jun; 43(6):615-21. PubMed ID: 12767361
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.